中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

750 records (took 0.033 seconds)

    METHOD AND SYSTEM FOR USING MIRRORED DATA TO DETECT CORRUPT DATA
    302.
    发明申请
    METHOD AND SYSTEM FOR USING MIRRORED DATA TO DETECT CORRUPT DATA 审中-公开
    使用镜像数据检测腐蚀数据的方法和系统

    公开(公告)号：WO1996041261A1

    公开(公告)日：1996-12-19

    申请号：PCT/US1996009257

    申请日：1996-06-05

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  GARY, Scott, P. ,  POPE, David, E. ,  CHANG, Tao

    IPC: G06F11/08

    CPC classification number: G06F11/167 ,  G06F11/08 ,  G06F2201/865 ,  G11C29/74

    Abstract: Errors in data stored in the memory of a computer are detected prior to use of the data. A protected data type is declared in writing a program in which errors in critical must be detected before the data are used. The invention is preferably implemented on a personal computer system (10) or in a microcontroller for a device. When a protected data item is initialized, both the protected data item and its corresponding bit-inverted form are stored in memory. A constructor function is used to determine the bit-inverted form. Any time that the protected data item is subsequently accessed for use by an application program, either the stored protected data item or its corresponding bit-inverted form are inverted for comparison to the other stored data item. Any difference detected in this comparison indicates that a change has occured in either or both of the protected data item and its corresponding bit-inverted form within memory. Depending upon the application progam in which the invention is used, an appropriate action is taken upon detecting such an error, such as providing an indication of the error and terminating further execution of the program.

    Abstract translation: 在使用数据之前检测存储在计算机存储器中的数据的错误。 一个受保护的数据类型是在编写程序之前被声明的，在这个程序中，在使用数据之前必须检测到关键的错误。 本发明优选地在个人计算机系统（10）或设备的微控制器中实现。 当受保护的数据项被初始化时，受保护的数据项及其对应的位反转形式被存储在存储器中。 构造函数用于确定位反转形式。 随后受保护的数据项随后被访问以供应用程序使用，所存储的受保护数据项或其对应的位反转形式被反转，以与其他存储的数据项进行比较。 在该比较中检测到的任何差异表示在存储器内的受保护数据项和其对应的位倒置形式中的一个或两个中发生了改变。 根据使用本发明的应用程序，在检测到这种错误时采取适当的动作，例如提供错误的指示并终止程序的进一步执行。

    BUFFER COMPOSITION FOR REAGENTS FOR IMMUNOASSAY
    303.
    发明申请
    BUFFER COMPOSITION FOR REAGENTS FOR IMMUNOASSAY 审中-公开
    用于免疫试剂的缓冲剂组合物

    公开(公告)号：WO1996041164A1

    公开(公告)日：1996-12-19

    申请号：PCT/US1996007745

    申请日：1996-05-24

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  FIGARD, Steve, D.

    IPC: G01N33/50

    CPC classification number: G01N33/531 ,  G01N33/5306 ,  G01N33/54393 ,  G01N33/5767 ,  Y10S436/82 ,  Y10S436/826

    Abstract: An aqueous composition suitable for use when performing immunological procedures. The composition includes at least one biological buffer, dithiothreitol (alternatively referred to herein as "DTT"), and ethylene glycol. The composition can also include at least one biological detergent, at least one source of positive and negative counterions, e.g., salt, and at least one viscosity modifier, e.g., sugar. The buffer also can include at least one preservative, such as sodium azide. The pH of the composition preferably ranges from about 6.4 to 7.2. A kit containing the composition is also disclosed.

    Abstract translation: 适合在进行免疫程序时使用的水性组合物。 组合物包括至少一种生物缓冲液，二硫苏糖醇（本文中称为“DTT”）和乙二醇。 组合物还可以包括至少一种生物洗涤剂，至少一种正和负抗衡离子源，例如盐，和至少一种粘度调节剂，例如糖。 缓冲液还可以包括至少一种防腐剂，例如叠氮化钠。 组合物的pH优选为约6.4至7.2。 还公开了含有该组合物的试剂盒。

    HETEROCYCLIC SUBSTITUTED CYCLOPENTANE COMPOUNDS
    305.
    发明申请
    HETEROCYCLIC SUBSTITUTED CYCLOPENTANE COMPOUNDS 审中-公开
    杂环取代的环戊二烯化合物

    公开(公告)号：WO1996040686A1

    公开(公告)日：1996-12-19

    申请号：PCT/US1996009042

    申请日：1996-06-06

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  BHAGWAT, Shripad, S. ,  COWART, Marlon, Daniel

    IPC: C07D487/04

    CPC classification number: C07D473/00 ,  C07D471/04 ,  C07F9/6561 ,  Y02P20/55

    Abstract: The present invention provides new heterocyclic substituted cyclopentane compounds of formula (I), wherein X is -N or -CR7, where R7 is hydrogen, halogen, loweralkyl, loweralkoxy or -S-loweralkyl; Y is -N or -CH; R1 and R2 are each independently hydrogen, hydroxy, alkoxy, or acyloxy or R1 and R2 are both hydroxy protected with an individual hydroxy protecting group or with a single dihydroxy-protecting group or R1 and R2 are absent and there is a double bond between the carbon atoms to which R1 and R2 are attached; R3 is hydrogen, hydroxy, loweralkyl or alkoxy; R4 is (a) hydrogen, (b) amino, (c) halogen, (d) hydroxy, (e) sulfonamido, (f) -P(O)(OH)2, (g) -P(O)-R8R9, wherein R8 and R9 are each independently hydrogen, hydroxy, loweralkyl, aryl or arylalkyl, (h) -NHR10, wherein R10 is hydrogen or an amino protecting group, (i) -NHC(O)NHR11, where R11 is hydrogen or loweralkyl, or (j) -A-R12 wherein A is O, S(O)n or -N(R13)- wherein R13 is hydrogen or loweralkyl, n is zero, one or two, and R12 is hydrogen, loweralkyl, alkylsulfonyl, acyl, alkoxycarbonyl, aryl, heteroaryl, arylalkyl, arylsulfonyl, haloalkyl, heteroarylalkyl, heteroarylsulfonyl, aminoalkyl or heterocyclic or (k) R4 is a ring N-member of a heteroaryl or heterocycle; or R3 and R4 taken together are =O, or taken together with the carbon atom to which they are attached, form a spirocyclic ring; R5 is hydrogen, loweralkyl, aryl, arylalkyl, heteroaryl, amino, alkylamino, alkoxy, acylamino, arylalkynyl, arylamino, arylmercapto, alkylmercapto, halogen, heterocyclic, hydrazino, -NHC(O)NH2, or -NR14R15 wherein R14 and R15 are each independently hydrogen or an amino protecting group or -NR14R15 is a nitrogen containing heterocycle of 5 to 7 members; and R6 is loweralkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, alkoxycarbonyl, carboxy, aryl, heteroaryl, heteroarylalkyl, arylalkyl, arylalkenyl, arylalkynyl, cyano, halogen, heteroarylalkynyl, or -C(O)NHR16, wherein R16 is alkyl, aryl, or heterocyclic. The present invention also provides pharmaceutical compositions containing such compounds and methods of using such compounds for inhibiting adenosine kinase.

    Abstract translation: 本发明提供新的式（I）的杂环取代的环戊烷化合物，其中X是-N或-CR 7，其中R 7是氢，卤素，低级烷基，低级烷氧基或-S-低级烷基; Y是-N或-CH; R 1和R 2各自独立地为氢，羟基，烷氧基或酰氧基，或者R 1和R 2均用单独的羟基保护基或单个二羟基保护基进行羟基保护，或者R1和R2不存在，并且在 R1和R2所连接的碳原子; R3是氢，羟基，低级烷基或烷氧基; R4是（a）氢，（b）氨基，（c）卤素，（d）羟基，（e）亚磺酰氨基，（f）-P（O）（OH）2，（g）-P（O）-R8R9 其中R 8和R 9各自独立地是氢，羟基，低级烷基，芳基或芳基烷基，（h）-NHR 10，其中R 10是氢或氨基保护基，（i）-NHC（O）NHR 11，其中R 11是氢或低级烷基 ，或（j）-A-R12，其中A是O，S（O）n或-N（R13） - ，其中R13是氢或低级烷基，n是0,1或2，R12是氢，低级烷基，烷基磺酰基， 酰基，烷氧基羰基，芳基，杂芳基，芳基烷基，芳基磺酰基，卤代烷基，杂芳基烷基，杂芳基磺酰基，氨基烷基或杂环或（k）R4是杂芳基或杂环的环N-成员; 或R 3和R 4一起为= O，或与它们所连接的碳原子一起形成螺环; R5是氢，低级烷基，芳基，芳基烷基，杂芳基，氨基，烷基氨基，烷氧基，酰基氨基，芳基炔基，芳基氨基，芳基巯基，烷基巯基，卤素，杂环，肼基，-NHC（O）NH2或-NR14R15，其中R14和R15各自 独立地是氢或氨基保护基或-NR14R15是5-7个成员的含氮杂环; 芳基，芳基烯基，芳基炔基，氰基，卤素，杂芳基炔基或-C（O）NHR 16，其中R 16是烷基，芳基，杂芳基， 或杂环。 本发明还提供含有这些化合物的药物组合物和使用这些化合物抑制腺苷激酶的方法。

    AEROSOL DRUG FORMULATIONS CONTAINING VEGETABLE OILS
    306.
    发明申请
    AEROSOL DRUG FORMULATIONS CONTAINING VEGETABLE OILS 审中-公开
    含有蔬菜油的气溶胶药物制剂

    公开(公告)号：WO1996040089A2

    公开(公告)日：1996-12-19

    申请号：PCT/US1996009654

    申请日：1996-06-07

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  ADJEI, Akwete, L. ,  GUPTA, Pramod, K. ,  LEE, Dennis, Y.

    IPC: A61K09/72

    CPC classification number: A61K9/008 ,  A61K47/44 ,  Y10S514/937

    Abstract: Pharmaceutical compositions for aerosol delivery comprising (a) a medicament, (b) a non-chlorofluorocarbon propellant, and (c) a vegetable oil or a pharmaceutically acceptable derivative thereof, as well as a method for preparing such compositions in which unwanted aggregation of the medicament is prevented without the use of surfactants, protective colloids or cosolvents.

    Abstract translation: 用于气雾剂输送的药物组合物，其包含（a）药物，（b）非氯氟烃推进剂和（c）植物油或其药学上可接受的衍生物，以及制备这样的组合物的方法， 在不使用表面活性剂，保护性胶体或助溶剂的情况下，可以防止药物。

    BENZO[5.6]PYRANO[2.3.4-IJ]QUINOLIZINE AND BENZO[5.6]THIOPYRANO[2.3.4-IJ]QUINOLIZINE DERIVATIVES AS ANTIBACTERIAL AND ANTINEOPLASTIC AGENTS
    309.
    发明申请
    BENZO[5.6]PYRANO[2.3.4-IJ]QUINOLIZINE AND BENZO[5.6]THIOPYRANO[2.3.4-IJ]QUINOLIZINE DERIVATIVES AS ANTIBACTERIAL AND ANTINEOPLASTIC AGENTS 审中-公开
    苯并[5.6] PYRANO [2.3.4-IJ]喹唑啉和苯并[5.6]噻吩并[2.3.4-IJ]喹唑啉衍生物作为抗细菌和抗原性试剂

    公开(公告)号：WO1996037495A1

    公开(公告)日：1996-11-28

    申请号：PCT/US1996006813

    申请日：1996-05-13

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  CHU, Daniel, T. ,  LI, Qun ,  RAYE, Kathleen

    IPC: C07D491/16

    CPC classification number: C07D491/16

    Abstract: Benzo[5.6]pyrano[2.3.4-ij]quinolizine and benzo[5.6]thiopyrano[2.3.4-ij]quinolizine compounds having formula (I), wherein A is sulfur or oxygen; R is selected from the group consisting of hydroxy, protected-hydroxy, C1-C6-alkoxy, halo, amino, C1-C6-alkylamino, hydroxy-C1-C6-alkylamino, bicyclic nitrogen-containing heterocycle, nitrogen-containing aromatic heterocycle, and nitrogen-containing heterocycle; R is selected from the group consisting of hydrogen, halo, C1-C6-alkyl, or halo-C1-C6-alkyl; R is selected from the group consisting of hydrogen, C1-C6-alkyl or C5-C7-cycloalkyl; and R and R are independently selected from the group consisting of hydrogen, C1-C6-alkyl or C1-C6-alkoxyl, having utility as intermediates or having antibacterial or antineoplastic activity.

    Abstract translation: 苯并[5.6]吡喃并[2,3,4-ij]喹嗪和具有式（I）的苯并[5,6]噻喃并[2,3,4-ij]喹嗪化合物，其中A是硫或氧; R 1选自羟基，被保护的羟基，C 1 -C 6 - 烷氧基，卤素，氨基，C 1 -C 6烷基氨基，羟基-C 1 -C 6 - 烷基氨基，双环含氮杂环，含氮 芳族杂环和含氮杂环; R 2选自氢，卤素，C 1 -C 6 - 烷基或卤代-C 1 -C 6 - 烷基; R 3选自氢，C 1 -C 6 - 烷基或C 5 -C 7 - 环烷基; R 4和R 5独立地选自氢，C 1 -C 6烷基或C 1 -C 6烷氧基，其可用作中间体或具有抗细菌或抗肿瘤活性。

    SELF-EMULSIFYING FORMULATIONS OF LIPOPHILIC DRUGS
    310.
    发明申请
    SELF-EMULSIFYING FORMULATIONS OF LIPOPHILIC DRUGS 审中-公开
    LIPOPHILIC DRUGS的自我制剂配方

    公开(公告)号：WO1996036316A1

    公开(公告)日：1996-11-21

    申请号：PCT/US1996007155

    申请日：1996-05-17

    Applicant: ABBOTT LABORATORIES

    Inventor： ABBOTT LABORATORIES ,  LIPARI, John, M. ,  McCHESNEY-HARRIS, Lisa, L. ,  MEYER, Glenn, A. ,  WIELAND, John, J.

    IPC: A61K09/107

    CPC classification number: A61K47/22 ,  A61K9/4858 ,  A61K47/14

    Abstract: Self-emulsifying pharmaceutical pre-concentrate compositions comprising: (a) a lipophilic medicinal compound, (b) d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS), and (c) a lipophilic phase as well as pharmaceutical compositions comprising such pre-concentrates in combination with a sufficient amount of water to produce a stable emulsion.

    Abstract translation: 自乳化药物预浓缩组合物，其包含：（a）亲脂性药用化合物，（b）d-α-生育酚聚乙二醇1000琥珀酸酯（TPGS），和（c）亲脂相以及药物组合物， 浓缩与足够量的水组合以产生稳定的乳液。

Patent Agency Ranking